Frazier Healthcare Aims for First Biotech VC Fund After Financial Crisis
Alan Frazier has been on record for a long time saying that the traditional biotech venture model is broken, and in severe need of updating. He’s been working on a new strategy for the past seven years or so, but the approach is facing its biggest test ever as Frazier prepares to raise his first fund in the wake of the Lehman/Fannie/Freddie/AIG financial calamity of 2008.
Frazier is the founder and managing partner of Frazier Healthcare Ventures, a 20-year-old Seattle and Menlo Park, CA-based venture firm that has $1.8 billion under management. The firm’s last fund, Frazier Healthcare VI, assembled $600 million in November 2007 to put to work in biotech, medical device, and healthcare growth equity opportunties. Frazier hasn’t formally initiated a fundraising process with pensions, endowments and other institutions, but on average he has raised new venture funds roughly every three years. “It’s time for us to raise a new fund,” he says.
The big story this year in biotech venture capital is the sheer number of funds—most estimates are between one-fourth and one-half—that are thought to be slowly winding down as they struggle to show the returns that are needed to keep raising new funds. Frazier, during an interview at the JP Morgan Healthcare Conference last week, said he expects many peer firms—but not his—to “go into hibernation.” He’s forecasting his fund will be one of the survivors because it decided back in 2005 that it no longer made sense to build biotech companies that intend to go public, and that they needed to be tailor-made to be acquired by Big Pharma and Big Biotech companies.
“For a long time, we in the venture business created the wrong companies for [big companies] to buy,” Frazier says. “We’d build something with 150 employees and four projects, when what they want are 25 people and one project.” The payoff, he says, “has been pretty dramatic. Obviously, it takes a while for that kind of strategy to evolve.”
Like any firm that’s been around for a while, Frazier has its share of wins and losses (and it obviously prefers to talk about the wins). Seattle-based Calistoga Pharmaceuticals represented a 3.74x return on Frazier’s investment when it was acquired by Gilead Sciences last year for $375 million up front, although the return could rise to 6x Frazier’s investment if certain milestones are met. Other portfolio companies like Oakland, CA-based Cerexa, San Diego-based Calixa Therapeutics, Carmel, IN-based Marcadia Biotech, and Cambridge, MA-based Alnara Pharmaceuticals all ended up getting acquired in the last two years at multiples between 3.39x times original investment on the low end (Alnara) through 10.67x times investment on the high end (Marcadia), according to data published in a Frazier newsletter. There was even one rare IPO in the portfolio, from Boulder, CO-based Clovis Oncology (NASDAQ: CLVS).
Of course, there were less-happy events for Frazier in the past year, too. Seattle-based Calypso Medical Technologies—which raised more than $175 million in venture capital since its founding in 1999—was sold for $10 million last year, plus undisclosed milestones. And just a few months after announcing it attracted a big-name advisor in Tachi Yamada, the former head of global health at the Gates Foundation, he left to take a new job as chief medical and scientific officer of Takeda Pharmaceuticals in Japan.
Frazier says he doesn’t expect any big changes in strategy in the next fund. About 60 percent of the money will be allocated toward growth equity/buyouts, while the rest will go toward biopharmaceutical and medical device venture investments. The growth equity piece typically focuses on buying profitable healthcare companies (think kidney dialysis clinics) that Frazier believes can grow revenues quickly with an infusion of $25 million to $50 million. “Those companies are very dependable, delivering 2.5x to 3.5x kind of returns,” Frazier says.
One of the big themes he’s watching for are companies that don’t necessarily have a hot new drug or device, but do have a way of delivering healthcare more efficiently. “I see that as a great place to look to invest. Everything we do plays into saving the health system money,” Frazier says.
Looking at the more innovative side of the portfolio, there is more to worry about: the lackluster IPO market, concerns about unpredictable FDA regulations, and an increasingly tough climate for winning reimbursement from insurers. But Frazier says he still likes the model of building lean operations like Calistoga for sale, because those type of single-asset companies—when successful—can still attract an average of 10 bidders from the ranks of Big Pharma and Big Biotech, and generate 5x or better returns. The idea is to invest in a Series A round, a Series B round, generate some promising clinical data, and sell the company after holding it for three to three-and-a-half years, Frazier says.
“We’ll do preclinical work, Phase 1 work, and sell at the end of Phase 2a or 2b,” Frazier says. “It’s a predictable strategy. It’s not a matter of ‘do we wait around for the next IPO bubble to get our realizations?’ We can wait for good clinical results and go to the [acquisition] market.”
One of the tricks with biotech startups will be to invest in areas where the FDA is “friendly,” as Frazier put it. Those areas include niche cancer populations, anti-infectives, and drugs with companion diagnostics. Mass markets like diabetes, obesity, cardiovascular disease, and neurology are areas to stay away from because the regulatory hurdles are too high, he says.
Partly because of FDA requirements, the next Frazier fund will only look to make one or two medical device investments. But the FDA is only part of the reason. There’s also been so much medical device industry consolidation that the best startups there can typically only generate acquisition bids from two or three big players, Frazier says.
Just like in medical devices, there are almost surely going to be fewer big players in biotech VC land. And while that might mean fewer innovative ideas get funded, Frazier says it could end up being a healthy thing for the industry.
“There’s enough money out there to do a nice job on biopharma,” Frazier says. “The win/loss ratio will be better, and fewer bets will be made, but they’ll be made with more experienced entrepreneurs. I think we’ll come out more healthy.”